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Text S1. Coexistence endemic equilibria in the competition models prior to vaccination
• SI-2 model
The equilibria for this model are calculated by setting all equations (§2.2) in the main text equal to zero, with
ρ = 0. Besides the type 1 only and type 2 only endemic equilibria, the SI-2 model admits a coexistence
equilibrium given by:
S ∗ =
1
R0
I∗1 =
1
R0
( 1
σ1
− 2
(R0 − 1)σ1σ2 + σ1 + σ2
)
I∗2 =
1
R0
( 1
σ2
− 2
(R0 − 1)σ1σ2 + σ1 + σ2
)
I∗12 = 1 − (S ∗ + I∗1 + I∗2) (1)
where R0 = β/µ in the SI-2 framework. Stability of this pre-vaccine equilibrium requires:
σ1 >
σ2
(R0 − 1)σ2 + 1 ; σ2 >
σ1
(R0 − 1)σ1 + 1 .
For an illustration of these criteria, depending on σ1 and σ2 see Figure S1.
• SIS-2 model
We find the equilibria pre-vaccine by setting equations (§2.3) in the main text equal to zero (assuming ρ = 0),
and then simplify the expressions using R0 = β/(γ + µ). The endemic coexistence equilibrium is given by:
S ∗ =
1
R0
I∗1 = I2 =
R0 − 1
R0[2 + (κσ + σ)(R0 − 1)]
I∗11 = I
∗
22 =
κσ(R0 − 1)2
2R0[2 + (κσ + σ)(R0 − 1)]
I∗12 = 1 − (S ∗ + I∗1 + I∗2 + I∗11 + I∗22), (2)
where the indices specify carriage: whether single or double carrier of pathogen types of group 1, 2 or both.
Asymptotic analysis of the system reveals that stability of this equilibrium requires κ < 1.
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(b) Higher transmission intensity
Figure S1: Stability criteria on the competition coefficients σ1 and σ2 in the SI-2 model that guarantee stable coexistence between the
two pathogen types at the endemic equilibrium. The regions are computed by checking the eigenvalues of the Jacobian matrix evaluated at the
endemic equilibria. In our vaccination models, we consider parameter regimes of stable coexistence prior to vaccine introduction (white region),
where the vaccine targets type 1. Parameter values: a) β = 0.05, µ = 0.02 (R0 = 2.5); b) β = 0.1, µ = 0.02 (R0 = 5).
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Figure S2: Prevalence-odds-ratio (POR) of target type in vaccinated and non-vaccinated hosts vs. true relative risk in the SI-2 model. Type
1 can be dominant prior to vaccination (0.2 ≤ σ1/σ2 ≤ 1), or alternatively, type 2 can be dominant (0.2 ≤ σ2/σ1 ≤ 1). The coloured lines from
blue to red correspond to increasing values of the competition ratio, σ1/σ2 and σ2/σ1 from 0.2 to 1. Other parameter values: µ = 0.0167, ρ = 0.5.
Initial conditions at endemic equilibrium. Time is in units of years. The low transmission cases (β = 0.032), correspond to R0 = 1.9. While the
high transmission cases (β = 0.32) correspond to R0 = 19. POR(t) is closer to w than PR(t).
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Figure S3: Prevalence ratio can under-estimate relative risk for high β (SIS-2). Parameter values: σ = 1, γ = 0.6, µ = 0.02, ρ = 0.5 and β = 10,
κ is varied between 0.1 and 0.9 (colored lines from blue to red) to reflect different scenarios of within-group competition. The true risk ratio is
w = 0.8, which implies VE = 0.2. The worst discrepancy between PR and w is observed for κ close to 1, which leads to a negative deviation,
indicating an over-estimation of VE if PR were to be used for this purpose.
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Figure S4: Prevalence ratio in the SI-2 model (counting for mixed carriage I12). Type 1 can be dominant prior to vaccination (0.2 ≤ σ1/σ2 ≤ 1),
or alternatively, type 2 can be dominant (0.2 ≤ σ2/σ1 ≤ 1). The coloured lines from blue to red correspond to increasing values of the competition
ratio, σ1/σ2 and σ2/σ1 from 0.2 to 1. Parameters as in Figure 3 in the main text. The sensitivity to competition asymmetries decreases but the
discrepancy with w increases overall.
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Figure S5: Prevalence ratio in the SIS-2 model (counting for mixed carriage I12). Analogous to figure 4 in main text. We can see the
sensitivity of PR(t) to competition hierarchies (within/between group, represented by κ), reflected in the blue to red lines, increases, especially for
large transmission intensity. This indicates that mixed multiple carriage holds important information about indirect vaccine effects, but may be
unsuitable to include in the analyses aimed at extracting true relative risk.
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Text S2. The SIR-2 model
Model structure and assumptions
In this model, we change the SI-2 model, assuming hosts recover with life-long type-specific immunity, at rate γ.
They enter these recovery classes: R1, refers to those that are immune against type 1 but can acquire type 2; R2, refers
to those that are immune against type 2 but can acquire type 1, and R12, describes hosts immune to both circulating
types. Singly infected hosts with type 1, and immune to type 2 are denoted by I1(2), and viceversa. Hosts infected
with type 2, but immune against type 1, are denoted by I2(1). Both these types of hosts contribute now to the forces of
infection λ1 and λ2. Vaccination (status denoted by subscript 0/1) acts as before, against type 1, with partial protection,
given by the factor w(0 ≤ w ≤ 1). After hosts experience multiple infection with both types, or sequential infection
by two types, they recover with full immunity to both types R12. Clearance of single and double carriage is assumed
to occur at equal rates, as in the earlier models. We assume no cross-immunity.
Non-vaccinated hosts
dS 0
dt = µ(1 − ρ) − (λ1 + λ2)S 0 − µS 0
dI01
dt = λ1S
0 − I01σ1λ2 − (µ + γ)I01
dI02
dt = λ2S
0 − I02σ2λ1 − (µ + γ)I02
dI012
dt = σ1λ2I
0
1 + σ2λ1I
0
2 − (µ + γ)I012
dR01
dt = γI
0
1 − λ2R01 − µR01
dR02
dt = γI
0
2 − λ1R02 − µR02
dR012
dt = γ(I
0
12 + I
0
2(1) + I
0
1(2)) − µR012
dI02(1)
dt = λ2R
0
1 − (µ + γ)I02(1)
dI01(2)
dt = λ1R
0
2 − (µ + γ)I01(2)

Vaccinated hosts
dS 0
dt = µρ − (wλ1 + λ2)S 1 − µS 1
dI11
dt = wλ1S
1 − I11σ1λ2 − (µ + γ)I11
dI12
dt = λ2S
1 − I12σ2λ1 − (µ + γ)I12
dI112
dt = σ1λ2I
1
1 + wσ2λ1I
1
2 − (µ + γ)I112
dR11
dt = γI
1
1 − λ2R11 − µR11
dR12
dt = γI
1
2 − wλ1R12 − µR12
dR112
dt = γ(I
1
12 + I
1
2(1) + I
1
1(2)) − µR112
dI12(1)
dt = λ2R
1
1 − (µ + γ)I12(1)
dI11(2)
dt = wλ1R
1
2 − (µ + γ)I11(2)
where
λ1 = β(I01 + I
0
12/2 + I
0
1(2) + I
1
1 + I
1
12/2 + I
1
1(2))
λ2 = β(I02 + I
0
12/2 + I
0
2(1) + I
1
2 + I
1
12/2 + I
1
2(1)).
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Inference under the SIR-2 model
We generate hypothetical trajectories using the SIR-2 equations, for given coverage ρ, demographic parameter µ
and clearance rate γ (e.g. Figure S3 a). The prevalence ratio of type 1 pathogen in vaccinated and non-vaccinated
hosts still shows significant deviation from the true vaccine protection parameter w (Figure S3 b).
For model-based inference, we vary the other four parameters: β representing the transmission rate, w, describing
vaccine protection against type 1 where vaccine efficacy is VE = 1 − w, and the direct competition parameters σ1
and σ2 acting at co-infection. By sampling the pathogen type prevalences at different time points post-vaccination,
and fitting the dynamic model to these ‘data’, we can recover back the original parameters. We group observations
into pathogen-free hosts: S + R1 + R2 + R12, hosts carrying type 1: I1 + I1(2), hosts carrying type 2: I2 + I2(1), and
hosts carrying both types I12. We do this grouping both for vaccinated and non-vaccinated hosts. Given that all
host proportions sum to 1, this results in 6 data points at each snapshot considered. If observations are perfect, the
backward inference works very well: all four parameters can be estimated accurately from model trajectories, even
when the prevalence proportions are extremely low (data not shown). As we realistically allow for sampling error,
we superimpose a multinomial sampling process on the deterministic model proportions, and then apply nonlinear
least squares optimization to the resulting synthetic sample proportions. In this case, larger sample sizes are needed to
identify σ1 and σ2, because the expected pathogen prevalence (and consequently of constituent subtypes) is rather low
in a SIR-2 framework. As γ decreases, the prevalence of infection increases (and there are less immune individuals),
augmenting our statistical power for the inference of competition parameters, for a given sample size (Figure S4 c-d).
The inference of β and w = 1 − VE is however accurate, even in the presence of observation error.
Notice that here we have assumed that the serological status of sampled individuals is not known, which may not
always be the case with ever advancing molecular technologies. Thus model fitting was performed only on aggregated
carriage status variables. It is likely that if the serological status (naive/immune to 1/immune to 2/ immune to both)
is known, we will have much more power to extract competition parameters σ1 and σ2 by fitting all the ODE’s to the
complete data, even when γ is large.
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(a) Dynamics in the years post-vaccination
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Figure S6: SIR-2 model framework. a) The lines show dynamics post-vaccination for β = 2, γ = 0.2, µ = 0.0167, and different competition
coefficients σ1 (<=> σ2 = 0.25). The endemic pre-vaccine equilibrium is assumed as initial conditions. Vaccination is implemented at time t = 0
with coverage ρ = 0.5 and vaccine efficacy VE = 0.5. Average life-expectancy of any individual in the population is 1/µ, assumed 60 years. The
panels illustrate oscillatory prevalences of type 1 and type 2 in the entire population (left), and in the vaccinated and non-vaccinated hosts (right).
Such oscillations are typical of an SIR framework, making the sensitivity of dynamic prevalences to σ1 and σ2 only moderate. b) Prevalence
ratio in the years post-vaccination, does not reflect accurately the true relative risk in the SIR-2 model, and there is minimal sensitivity to direct
competition parameters.
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Figure S7: Dynamic model fitting in the SIR-2 framework tested for random parameter combinations. a)-b) Bias and parameter range in
the high clearance rate scenario, thus smaller prevalence at endemic equilibrium pre-vaccination. c)-d) Bias and parameter range in the smaller
clearance rate case, thus lower prevalence of carriage at endemic equilibrium pre-vaccination. The parameters are ordered as β,w, σ1, σ2. We
simulated the model for 150 different parameter combinations. Fixed parameter values: µ = 0.0167, ρ = 0.5, sample size N = 5000. Initial
conditions are always fixed at pre-vaccine endemic equilibrium (solved numerically for each parameter combination). The time points (years in
this model) post-vaccination used are ti = 5, 10, 20, 30, where the population is sampled multinomially for infection status (uninfected, infected
with type 1, with type 1, with both). The performance of the method to estimate the competition coefficients σ1 and σ2 in the SIR-2 model
depends on the prevalence that can be observed in a population. Lower rate of recovery γ leads to higher prevalence of infection, thus enables
better estimation of σ1, σ2, for same N, due to less sampling error. The inference of β and vaccine efficacy remains remarkably stable.
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Figure S8: Parameter correlation in the SIS-2 model. Parameters κ and VE may appear correlated at one scale, namely, if only global prevalence
of target types at a given time post-vaccination is available: Prev (type 1) = I1 + I11 + I12/2 (contour plot on the left). However, when one zooms
further into each scenario (marked white dots), by using the information contained in the finer-scale epidemiological variables: S , I1, I2, I11, I22, I12
across vaccinated (listed 1-6) and non-vaccinated individuals (listed 7-12), differing between A and B (right sub-panels), the parameters κ and
VE should be suitably detangled. Fixed parameter values β = 6, µ = 0.02, γ = 0.6, ρ = 0.5, σ = 1. Initial conditions at pre-vaccine endemic
equilibrium.
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